Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news

Sex Differences in HBV-Associated Liver Cancer Sex Differences in HBV-Associated Liver Cancer
Liver cancer genetics and biology differ between men and women and help explain why aflatoxin exposure increases the risk in hepatitis B virus (HBV) –infected patients, particularly in men.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 5, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Hepatitis B vaccine: What to know to protect yourself
Hepatitis is inflammation in the liver caused by specific viruses. The hepatitis viruses are referred to as types A, B, C, D and E. All types affect the liver, but they differ in illness severity and prevention options. In the U.S., the most common forms are hepatitis A, hepatitis B and hepatitis C. Acute or chronic hepatitis B Hepatitis B is a serious disease caused by a virus that attacks the liver. It's one of the more… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 13, 2022 Category: Databases & Libraries Source Type: news

Emergency department opt out testing for HIV, hepatitis B and hepatitis C: The first 100 days
This report describes the progress, challenges, results and learning of the first 100 days of an initiative to implement opt out testing for HIV, hepatitis B and hepatitis C in emergency departments in the parts of England with the highest diagnosed prevalence of HIV infection. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 5, 2022 Category: Consumer Health News Source Type: news

Bepirovirsen Studied for Treatment of Chronic Hepatitis B Infection
MONDAY, Nov. 14, 2022 -- A 300-mg dose of bepirovirsen per week for 24 weeks results in sustained hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA loss in 9 to 10 percent of patients with chronic HBV infection, according to a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2022 Category: General Medicine Source Type: news

What Are the Potential Benefits and Risks of Premasticated Foods?
Discussion Premastication is the prechewing of foods or medicines by another person before feeding to an infant. It is also used to pretaste or temperature test foods. It was a common practice for millennia, especially before modern food technology, as a way to transition an infant from a solely liquid based diet to a mixed diet mainly of solid food. Rates of premastication vary, with less developed countries having an increased incidence/prevalence (up to 50%) but it is not uncommon in developed countries (in the US 14% is reported). Saliva is also used to clean other people, treat cuts/itches or insect bites as well. Pla...
Source: PediatricEducation.org - November 14, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Chronic HBV Infections Associated With Liver Malignancies Chronic HBV Infections Associated With Liver Malignancies
Treatment with nucleos(t)ide analogues lowers risk of extrahepatic cancer in patients with hepatitis B infections.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 12, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news

Novel Hepatitis B Drug Hints at Long-Term 'Functional Cure' for Some in Early Trial
(MedPage Today) -- WASHINGTON -- Investigational antisense RNA-based therapy bepirovirsen sustained clearance of both hepatitis B virus (HBV) DNA and surface antigen (HBsAg) for a modest proportion of patients out to 6 months after injections... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 11, 2022 Category: Gastroenterology Source Type: news

Tenofovir, Vaccine Combo Eliminates Mom-to-Child HBV Transmission
(MedPage Today) -- Earlier maternal tenofovir disoproxil fumarate (TDF) combined with infant vaccination completely eliminated vertical transmission of chronic hepatitis B virus (HBV) from highly viremic mothers, even without the use of hepatitis... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 8, 2022 Category: Gastroenterology Source Type: news

New data buoy hopes for promising malaria vaccine —but questions remain
A new vaccine against malaria showed promising preliminary results in a large trial in four African countries, boosting hopes that an additional tool may soon be available to help control the deadly disease. The vaccine, named R21/Matrix-M and developed by researchers at the University of Oxford, produced similarly impressive results in a small trial last year , but the current study posed a stiffer test of its protection. Initial data from the trial, reported yesterday at the American Society of Tropical Medicine and Hygiene meeting in Seattle, suggest the vaccine had an efficacy higher than 70% in...
Source: ScienceNOW - November 3, 2022 Category: Science Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. Food and Drug Administration Approves Vemlidy (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Approval Expands on Previous FDA Approval of Vemlidy in Adults Living With This Chronic Liver Disease Efficacy and Safety of Once-Daily Vemlidy Demonstrated in Individuals 12 Years of Age and Older FOSTER CITY, Calif.--(BUSINESS WIRE) November... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 2, 2022 Category: Drugs & Pharmacology Source Type: news

Biohazard accidents, harmful elements to the wellness of healthcare workers, and their risk factors - Tejada-P érez JJ, Herrera-Burgos MR, Parrón-Carreño T, Alarcón-Rodríguez R.
BACKGROUND: For healthcare personnel, biohazard accidents pose a significant risk to their health. These exposures can enable the transmission of pathogens such as Hepatitis B, Hepatitis C, and human immunodeficiency virus (HIV). OBJECTIVE: To indi... (Source: SafetyLit)
Source: SafetyLit - October 31, 2022 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news